Biogen CEO Pick Vounatsos Suggests A Return To Commercial Focus

Biogen’s Chief Commercial Officer Michel Vounatsos will succeed CEO George Scangos effective Jan. 6. The appointment of the longtime Merck executive appears to suggest a renewed emphasis on the commercial landscape for a big biotech that has recently played up R&D.

The appointment of Biogen Inc.’s Chief Commercial Officer Michel Vounatsos to succeed George Scangos as CEO effective Jan. 6 suggests a renewed emphasis on commercial growth at a time when the company needs to squeeze growth out of its marketed products, particularly in the core area of multiple sclerosis, and fill a late-stage pipeline gap.

Biogen announced the new CEO after market close Dec. 19 and investors reacted with the stock dropping 2.7% on the...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Skyhawk Looks To Soar With Huntington’s Hope

19 Jun 2025

• By Kevin Grogan

Oral RNA splicing modulator has gone into a Phase II/III trial

Draig Is All Fired Up To Transform Neuropsychiatric Field

18 Jun 2025

• By Kevin Grogan

Wales-based group launches with $140m series A.

Supernus Secures Sage With CVR-Supported Deal

16 Jun 2025

• By Jessica Merrill

Supernus agreed to pay $561m upfront plus a contingent value right that could add $234m to buy Sage, topping a previously rejected offer from Biogen.

Who Dares Wins? Roche Moves Parkinson’s Candidate Into Phase III Despite Near Miss

16 Jun 2025

• By Andrew McConaghie

Open-label extension data have persuaded Roche to move prasinezumab into Phase III, where it believes a few tweaks to the study design could turn a near miss into success.